Edward A Fisher Selected Research

Apoproteins

1/2021	Short-Term Acyl-CoA:Cholesterol Acyltransferase Inhibition, Combined with Apoprotein A1 Overexpression, Promotes Atherosclerosis Inflammation Resolution in Mice.
8/2002	The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein b100.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Edward A Fisher Research Topics

Disease

110	Atherosclerosis 01/2022 - 02/2002
47	Inflammation (Inflammations) 01/2022 - 11/2003
47	Atherosclerotic Plaque (Atheroma) 01/2021 - 11/2004
30	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2005
12	Obesity 01/2021 - 04/2002
10	Hepatocellular Carcinoma (Hepatoma) 02/2014 - 02/2002
9	Hypercholesterolemia 01/2021 - 03/2003
8	Hyperglycemia 01/2022 - 06/2003
8	Hyperlipidemias (Hyperlipidemia) 10/2017 - 01/2004
7	Insulin Resistance 10/2020 - 07/2002
6	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 10/2004
6	Hypoxia (Hypoxemia) 01/2021 - 10/2011
6	Myocardial Infarction 01/2019 - 03/2009
5	Neoplasms (Cancer) 08/2015 - 06/2010
4	Necrosis 01/2022 - 09/2002
4	Body Weight (Weight, Body) 01/2021 - 09/2010
4	Dyslipidemias (Dyslipidemia) 01/2021 - 09/2004
4	Diabetes Mellitus 11/2020 - 10/2014
3	Weight Loss (Weight Reduction) 01/2020 - 05/2014
3	Metabolic Diseases (Metabolic Disease) 01/2020 - 04/2008
3	Infections 11/2017 - 04/2010
3	Hypertriglyceridemia 01/2015 - 10/2011
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2020 - 05/2011
2	Non-alcoholic Fatty Liver Disease 01/2020 - 11/2013
2	Morbid Obesity 01/2019 - 01/2019
2	Coronary Artery Disease (Coronary Atherosclerosis) 12/2018 - 07/2013
2	Thrombosis (Thrombus) 01/2018 - 01/2017
2	Type 2 Diabetes Mellitus (MODY) 06/2017 - 01/2017
2	Pathologic Processes 01/2017 - 05/2011
2	Vascular Diseases (Vascular Disease) 09/2014 - 07/2011

Drug/Important Bio-Agent (IBA)

48	CholesterolIBA 01/2021 - 09/2003
34	LipidsIBA 01/2022 - 05/2004
30	Apolipoproteins E (ApoE)IBA 01/2021 - 06/2002
28	HDL LipoproteinsIBA 01/2021 - 10/2004
26	ApolipoproteinsIBA 01/2020 - 02/2002
19	Lipoproteins (Lipoprotein)IBA 01/2021 - 02/2002
15	oxidized low density lipoproteinIBA 01/2019 - 10/2004
15	Contrast MediaIBA 06/2013 - 11/2004
12	LDL Receptors (LDL Receptor)IBA 01/2022 - 03/2003
9	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2019 - 09/2008
8	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2013
8	Messenger RNA (mRNA)IBA 01/2021 - 04/2010
8	LDL CholesterolIBA 01/2018 - 03/2003
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 03/2009
7	Triglycerides (Triacylglycerol)IBA 01/2021 - 02/2002
7	LDL Lipoproteins (beta Lipoproteins)IBA 01/2021 - 02/2006
7	Liver X ReceptorsIBA 10/2017 - 04/2008
6	CytokinesIBA 01/2022 - 06/2017
6	RNA (Ribonucleic Acid)IBA 01/2021 - 02/2002
6	HDL CholesterolIBA 01/2020 - 03/2008
5	LigandsIBA 04/2021 - 05/2014
5	Netrin-1IBA 01/2021 - 01/2012
5	Biological ProductsIBA 01/2021 - 11/2004
5	CollagenIBA 01/2021 - 10/2004
5	Glucose (Dextrose)FDA LinkGeneric 11/2020 - 01/2015
5	microsomal triglyceride transfer proteinIBA 01/2017 - 02/2002
5	VLDL LipoproteinsIBA 02/2016 - 05/2004
4	Apolipoproteins B (ApoB)IBA 01/2022 - 05/2004
4	Interleukin-6 (Interleukin 6)IBA 04/2021 - 06/2017
4	C-Reactive ProteinIBA 04/2021 - 01/2018
4	Oxidants (Oxidizing Agents)IBA 01/2018 - 05/2004
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2015 - 12/2002
4	Peroxidase (Myeloperoxidase)IBA 04/2014 - 12/2012
4	Small Interfering RNA (siRNA)IBA 02/2014 - 04/2010
4	GadoliniumIBA 06/2013 - 09/2006
4	Transcription Factors (Transcription Factor)IBA 06/2013 - 02/2005
3	Interleukin-4 (Interleukin 4)IBA 01/2022 - 01/2017
3	ChemokinesIBA 04/2021 - 01/2012
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2020 - 06/2017
3	Chemokine ReceptorsIBA 06/2015 - 03/2006
3	Insulin (Novolin)FDA Link 01/2015 - 05/2011
3	AntioxidantsIBA 12/2012 - 05/2004
2	Indicators and Reagents (Reagents)IBA 04/2021 - 08/2004
2	Biomarkers (Surrogate Marker)IBA 04/2021 - 10/2020
2	ApoproteinsIBA 01/2021 - 08/2002
2	Serine (L-Serine)FDA Link 01/2021 - 01/2020
2	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 01/2021 - 10/2016
2	Cholesterol Esters (Cholesteryl Esters)IBA 01/2021 - 10/2019
2	CalciumIBA 01/2021 - 07/2011
2	Vitamin A (Retinol)FDA LinkGeneric 11/2020 - 01/2017
2	Receptor for Advanced Glycation End ProductsIBA 11/2020 - 06/2017
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2020 - 03/2006
2	Antisense OligonucleotidesIBA 01/2020 - 01/2018
2	Scavenger Receptors (Scavenger Receptor)IBA 01/2019 - 09/2006
2	InflammasomesIBA 01/2019 - 01/2017
2	OligonucleotidesIBA 01/2018 - 07/2011
2	TNF Receptor-Associated Factor 6 (TRAF6)IBA 01/2018 - 01/2018
2	Plasminogen Activators (Plasminogen Activator)IBA 11/2017 - 01/2010
2	Simvastatin (Zocor)FDA LinkGeneric 04/2015 - 01/2004
2	GW 3965IBA 01/2015 - 09/2014
2	Streptozocin (Streptozotocin)FDA Link 10/2014 - 06/2011
2	Tyrosine (L-Tyrosine)FDA Link 04/2014 - 09/2013
2	GoldIBA 11/2013 - 09/2010
2	Methionine (L-Methionine)FDA Link 09/2013 - 12/2002

Therapy/Procedure

21	Therapeutics 01/2022 - 12/2010
6	Transplantation 10/2021 - 05/2007
4	Bariatric Surgery 10/2020 - 01/2019
2	Gastric Bypass (Roux-en-Y Gastric Bypass) 10/2020 - 05/2014
2	Gastrectomy 10/2020 - 01/2019
2	Injections 04/2014 - 01/2014